RATIONALE: Varenicline represents a new class of smoking cessation aids that has different mechanisms of action that are unique from bupropion or nicotine replacement therapies. An improved understanding of these mechanisms may lead to greater treatment success in quitting smoking. OBJECTIVES: We examined the effects of steady-state varenicline on attention and inhibitory control among adult treatment-seeking smokers. METHODS:Adult smokers enrolled in a randomized clinical trial received either 4 weeks of pre-quit varenicline (n = 31) or 3 weeks of placebo (n = 26) followed by 1 week of standard varenicline treatment. Participants in the present work completed cognitive assessments at a baseline session (prior to treatment) and again 3 weeks later (during active treatment). At both sessions, participants completed the stop signal task to assess both lapses in attention and inhibitory control. RESULTS: Analyses indicated that varenicline improved lapses in attention compared to placebo. There were no significant differences observed between groups at either session for inhibitory control. CONCLUSIONS: The present study demonstrated that varenicline improves lapses in attention among treatment-seeking smokers preparing to make a quit attempt. These findings suggest that the domain of attention may be a good candidate for larger studies of the role of improved cognition in understanding the mechanisms of varenicline treatment for smoking cessation.
RCT Entities:
RATIONALE: Varenicline represents a new class of smoking cessation aids that has different mechanisms of action that are unique from bupropion or nicotine replacement therapies. An improved understanding of these mechanisms may lead to greater treatment success in quitting smoking. OBJECTIVES: We examined the effects of steady-state varenicline on attention and inhibitory control among adult treatment-seeking smokers. METHODS: Adult smokers enrolled in a randomized clinical trial received either 4 weeks of pre-quit varenicline (n = 31) or 3 weeks of placebo (n = 26) followed by 1 week of standard varenicline treatment. Participants in the present work completed cognitive assessments at a baseline session (prior to treatment) and again 3 weeks later (during active treatment). At both sessions, participants completed the stop signal task to assess both lapses in attention and inhibitory control. RESULTS: Analyses indicated that varenicline improved lapses in attention compared to placebo. There were no significant differences observed between groups at either session for inhibitory control. CONCLUSIONS: The present study demonstrated that varenicline improves lapses in attention among treatment-seeking smokers preparing to make a quit attempt. These findings suggest that the domain of attention may be a good candidate for larger studies of the role of improved cognition in understanding the mechanisms of varenicline treatment for smoking cessation.
Authors: Hans Rollema; Mihály Hajós; Patricia A Seymour; Rouba Kozak; Mark J Majchrzak; Victor Guanowsky; Weldon E Horner; Doug S Chapin; William E Hoffmann; David E Johnson; Stafford McLean; Jody Freeman; Kathryn E Williams Journal: Biochem Pharmacol Date: 2009-06-06 Impact factor: 5.858
Authors: Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: John R Hughes; Stephen I Rennard; James R Fingar; Sandy K Talbot; Peter W Callas; Karl O Fagerstrom Journal: Nicotine Tob Res Date: 2011-06-07 Impact factor: 4.244
Authors: H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams Journal: Neuropharmacology Date: 2006-12-08 Impact factor: 5.250
Authors: Sarah V Spencer; Larry W Hawk; Jerry B Richards; Keri Shiels; William E Pelham; James G Waxmonsky Journal: J Abnorm Child Psychol Date: 2009-08
Authors: Josette G Harris; Susan Kongs; Diana Allensworth; Laura Martin; Jason Tregellas; Bernadette Sullivan; Gary Zerbe; Robert Freedman Journal: Neuropsychopharmacology Date: 2004-07 Impact factor: 7.853
Authors: Yong Cui; Jeffrey M Engelmann; Jonathan Xian; Jennifer A Minnix; Cho Y Lam; Maher Karam-Hage; Paul M Cinciripini; Jason D Robinson Journal: Int J Psychophysiol Date: 2017-12-06 Impact factor: 2.997
Authors: Claire E Wilcox; Vince D Calhoun; Srinivas Rachakonda; Eric D Claus; Rae A Littlewood; Jessica Mickey; Pamela B Arenella; Kent E Hutchison Journal: Psychiatry Res Neuroimaging Date: 2017-04-30 Impact factor: 2.376